Background

During the pandemic, the global biotech industry experienced severe supply chain bottlenecks. While the Pfizer-BioNTech and Moderna vaccines were distributed at unprecedented speeds, securing raw materials for core delivery systems posed a significant bottleneck in each manufacturing process. mRNA molecules are inherently negatively charged and vulnerable to enzymatic degradation, making it difficult to deliver them into target cells. Lipid nanoparticles (LNPs) are the key carriers that protect them and deliver them into the cytoplasm.

Among the four major lipid components of LNPs, the substance that substantially determines in vivo delivery efficiency is the ionizable lipid (IL). It remains uncharged in physiologically neutral environments but becomes positively charged under the acidic conditions inside endosomes, thereby disrupting the endosomal membrane. However, an excessive dependence on specific patented lipids used in commercial vaccines exposed formulation vulnerabilities, making it difficult to respond flexibly when global supply instabilities occurred. To achieve raw material diversification and next-generation formulation design, it was necessary to precisely identify the systematic correlation between the lipid molecular structure, internal particle arrangement, intracellular behavior, and the final immune response.

Key Findings

A joint international research team, including King Abdullah University of Science and Technology (KAUST) in Saudi Arabia, selected five types of ionizable lipids to systematically compare and analyze the internal nanostructure of LNPs, mRNA delivery capability, and immunogenicity. The research team prepared five formulations with distinct molecular structures and conducted experiments to contrast the internal microstructure of the particles with their in vivo efficacy.

Physicochemical analysis revealed that the internal structure of LNPs was not limited to simple spherical particles. Within the formulations, complex phase separation patterns were observed, where liquid crystalline lamellar (L-alpha) and inverse hexagonal (H-II) phases coexisted, or regions loaded with genetic material mixed with unloaded regions. In particular, Lipid-5, which possesses a saturated multi-tail chain structure, and SM-102, a component of the Moderna vaccine formulation, strongly induced the formation of inverse hexagonal phases and membrane fusion intermediates. The inverse hexagonal arrangement promotes interaction with the cell membrane to assist endosomal escape in acidic environments, ultimately leading to the highest levels of in vivo protein expression in animal models.

In contrast, the cKK-E12 formulation, which possesses two ionizable head structures, showed a tendency to form lamellar-like layered structures. This structural characteristic resulted in decreased mRNA encapsulation efficiency and significantly lower transfection efficiency both in vitro and in vivo. This proved that the stereochemical shape of the lipid head and tail is a key factor determining the phase transition within the nanoparticles.

A surprising twist emerged in the immunogenicity evaluation. All five tested formulations succeeded in inducing strong binding and neutralizing antibodies in mouse models. Surprisingly, the final antibody titers induced by the Lipid-5 and SM-102 formulations, which exhibited significantly higher protein expression levels, were actually lower than those of other formulations that had lower expression efficiency due to a higher proportion of lamellar structures. This result directly contradicts the common belief that higher intracellular antigen expression leads to stronger humoral immunity.

Implications and Outlook

This discovery poses important questions to the existing LNP development paradigm, which focused solely on maximizing protein expression. Until now, the biotech industry has primarily used luciferase or fluorescent protein expression levels as the main screening indicators when building new lipid libraries. The empirical data showing that high antigen protein expression does not directly translate to strong humoral immunity provides grounds to completely re-examine the evaluation system for vaccine delivery vehicles. The possibility that excessively high antigen expression might induce immune response saturation or cytotoxicity also cannot be ruled out.

Along with this, a theoretical foundation has been established to secure the structural safety of alternative lipid-based vaccine formulations, moving away from the dependence on specific commercial lipids. This is because it has become possible to design formulations that elicit optimal immunogenicity without the need for unnecessarily high doses by precisely controlling the internal crystalline phase arrangement of the lipids.

However, caution is warranted in extending the conclusions to all novel synthetic lipids with diverse scaffolds, as the study was limited to a specific panel of five lipid species. Follow-up studies that meticulously track pathway-specific differences in cell-mediated immune responses, including long-term memory B and T cells, are necessary to establish a comprehensive vaccine efficacy prediction model.